In the presence of oncogenic KRAS, IL-17 induces transcription of DCLK1 and ALDH1A1 (a marker of embryonic stem cells) through classical pathway activation, and directly upregulates DCLK1 expression in pancreatic cancer cells in a dose-dependent manner (110). This evidence concerns the gene IL17A and pancreatic neoplasm.